Preclinical Study Shows Anti-fibrotic Effects of Cancer Therapy for IPF Fibroblasts

This topic contains 0 replies, has 1 voice, and was last updated by  Pulmonary Fibrosis News Moderator 9 months ago.

  • Author
  • #15738

    Panobinostat, an approved treatment for multiple myeloma, exerts anti-fibrotic activity, inducing cell death and reducing the proliferation of lab-grown fibroblasts from idiopathic pulmonary fibrosis (IPF) patients, a preclinical study reports.

    The data also suggest that, despite an ability to inhibit cellular pathways involved in fibrosis, approved IPF therapy Esbriet (pirfenidone, marketed by Genentech) is not as effective as panobinostat in blocking the growth of IPF fibroblasts. Learn more here.

    Are you interested in updates on this research?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?


Create Account